--- title: "U.S. Stock Market Midday Update: Longevity Health down 7.07%" description: "Longevity Health fell 7.07%; Sarepta Therapeutics rose 18.54%, with a transaction volume of USD 1.007 billion; AbbVie rose 1.92%, with a transaction volume of USD 724 million; Ikonisys fell 16.34%, wi" type: "news" locale: "en" url: "https://longbridge.com/en/news/250648664.md" published_at: "2025-07-29T18:53:06.000Z" --- # U.S. Stock Market Midday Update: Longevity Health down 7.07% > Longevity Health fell 7.07%; Sarepta Therapeutics rose 18.54%, with a transaction volume of USD 1.007 billion; AbbVie rose 1.92%, with a transaction volume of USD 724 million; Ikonisys fell 16.34%, with a transaction volume of USD 434 million; Amgen rose 0.59%, with a market capitalization of USD 163 billion **U.S. Stock Market Midday Update** Longevity Health fell 7.07%, with increased trading volume. Based on recent important news: 1. On July 29, HengRui Medicine had a block trade of 13.59 million shares at a 4% discount, raising market concerns about pharmaceutical stocks, leading to a decline in Longevity Health's stock price. 2. On July 23, Junyao Health had a block trade at an 8.88% discount, which dampened market sentiment and affected related health stocks. 3. On July 23, Meinian Health had a block trade at a 6.73% discount, further exacerbating negative sentiment in the health industry. **Top Stocks by Industry Trading Volume** Sarepta Therapeutics rose 18.54%, with a trading volume of $1.007 billion. Based on recent important news: 1. On July 29, the FDA recommended lifting the pause on Sarepta's gene therapy Elevidys, causing the stock price to rise by 41.05%. 2. On July 29, Barclays raised Sarepta's target price from $10 to $22, further boosting the stock price. 3. On July 29, JP Morgan upgraded Sarepta's rating to neutral, considering the FDA's decision a clear victory. AbbVie rose 1.92%, with a trading volume of $724 million. Based on recent key news: 1. On July 29, AbbVie submitted an FDA approval application for the combination treatment of VENCLEXTA® and Acalabrutinib for CLL, driving the stock price up. 2. On July 29, Eli Lilly announced that its drug Jaypirca performed better in a head-to-head study against AbbVie's Imbruvica, undermining market confidence in AbbVie. 3. On July 28, AbbVie's drugs Skyrizi and Rinvoq exceeded expectations, boosting investor confidence. Iklisys fell 16.34%, with increased trading volume. Based on recent important news: 1. On July 29, Iklisys released its second-quarter financial report, with revenue falling short of expectations, leading to a 12% drop in stock price. 2. On July 29, Morgan Stanley lowered Iklisys's target price from $48 to $46, further dampening market confidence. 3. On July 29, the company announced the suspension of the STELLAR-305 Phase III trial and delayed the results of STELLAR-304, increasing market uncertainty. **Top Stocks by Industry Market Capitalization** Amgen rose 0.59%, with a market capitalization of $163 billion. Based on recent important news: 1. On July 28, Amgen was included in the Dow Jones Dividend Stock List, highlighting its dividend attractiveness, which pushed the stock price up by 0.59% 2. On July 29, analysts maintained a hold rating on Amgen, excluding it from the recommended list, limiting further price increases. 3. On July 27, the overall market trading volume increased, with retail investors active, driving stock price fluctuations ### Related Stocks - [XAGE.US - Longevity Health](https://longbridge.com/en/quote/XAGE.US.md) ## Related News & Research | Title | Description | URL | |-------|-------------|-----| | Blackstone-backed Liftoff Mobile files to withdraw US listing | Feb 17 (Reuters) - Blackstone-backed (BX.N) Liftoff Mobile has filed to withdraw its initial public offering plans in th | [Link](https://longbridge.com/en/news/276118530.md) | | Short Interest in Schneider Electric SE (OTCMKTS:SBGSY) Drops By 16.8% | Schneider Electric SE (OTCMKTS:SBGSY) experienced a 16.8% decrease in short interest in January, with 197,858 shares sho | [Link](https://longbridge.com/en/news/276071356.md) | | Mubadala Investment Co Pjsc Dissolves Share Stake in Salesforce, Verizon; Cuts in Disney | Mubadala Investment Co PJSC has significantly reduced its shareholding in Disney by 48.7%, now holding 35,984 shares. Th | [Link](https://longbridge.com/en/news/276145715.md) | | Mubadala Investment Co Pjsc Reports Share Stake In Pfizer, Abbvie, Dissolves in Merck, Dell | Mubadala Investment Co PJSC has reported its shareholdings as of December 31, 2025. The company holds 444,978 shares in | [Link](https://longbridge.com/en/news/276145564.md) | | Activist investor Jana Partners builds stake in Fiserv, WSJ reports | Feb 17 (Reuters) - Activist investor Jana Partners has built a stake in Fiservand is pressing the payments company to pu | [Link](https://longbridge.com/en/news/276121779.md) | --- > **Disclaimer**: This article is for reference only and does not constitute any investment advice.